Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosfomycin vs Meropenem or Ceftriaxone in MDR E. coli UTI
NCT02142751Phase 3Completed
- Sponsor
- Fundación Pública Andaluza para la Gestión de la Investigación
- Start
- Jul 2014
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fosfomycin in urinary tract infection (UTI) and Bacteremia (3 arms), sponsored by Fundación Pública Andaluza para la Gestión de la Investigación. Primary endpoint: Clinical and microbiological cure rate. Started Jul 2014; status: completed.
02
Drugs
fosfomycin
03
Conditions
urinary tract infection (UTI)Bacteremia
Beyond the preview
Go deeper on NCT02142751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02142751.